Technological Advances That Herald A Renaissance in Peptide Drug Discovery

October 15, 2020 11:00 AM - 12:00 PM

Webinar, click "live-stream" button to view

Add to Calendar 10/15/2020 11:00:56 AM 10/15/2020 12:00:56 PM Technological Advances That Herald A Renaissance in Peptide Drug Discovery

This forum will cover the area of therapeutic peptides and provide historical perspectives including the ups and downs of the field, current development trends, and future directions. We’ll discuss the role of artificial intelligence and machine learning in expanding the landscape of peptide drug discovery opportunities. And we’ll present a case study on targeting Pannexin 1 channels in disease. Questions are welcomed throughout the presentations and panel discussion.

Sponsored by the MassBio Drug Discovery forum working group.

NOTE: MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning.

Webinar, click "live-stream" button to view

This forum will cover the area of therapeutic peptides and provide historical perspectives including the ups and downs of the field, current development trends, and future directions. We’ll discuss the role of artificial intelligence and machine learning in expanding the landscape of peptide drug discovery opportunities. And we’ll present a case study on targeting Pannexin 1 channels in disease. Questions are welcomed throughout the presentations and panel discussion.

Sponsored by the MassBio Drug Discovery forum working group.

NOTE: MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning.

Vice President of Chemistry, Intarcia Therapeutics, and President, American Peptide Society
Dr. Ved Srivastava is Vice President of Chemistry at Intarcia Therapeutics and President of the American Peptide Society. Prior to Intarcia, he was co-founder and Vice President of peptide chemistry of Phoundry Pharmaceuticals. Phoundry was acquired by Intarcia Therapeutics in 2015. Prior to that, he was the Head of Peptide Chemistry at GlaxoSmithKline (USA), and in the senior leadership role at Amylin Pharmaceuticals. Ved has over 25 years of expertise in peptide medicinal chemistry, peptide drug delivery and chemistry manufacturing and control (CMC) with major emphasis in drug discovery and development in metabolic diseases, CNS, and inflammation therapeutic area. He has significantly contributed to the development of three peptide-based drugs ByettaTM, SymlinTM , and BydeureonTM for the treatment of diabetes. Ved has co-authored and published more than sixty peer-reviewed manuscripts, patents, and abstracts, and is editor of four recent books focused on peptide discovery and development - (1) Peptide Therapeutics CMC - Strategy for Chemistry Manufacturing and Control (2) Peptide-based Drug Discovery: Challenges and New Therapeutics, (3) Comprehensive Medicinal Chemistry III - Biologics Medicine -Vol 6 and (4) ‘Peptide 2015’. Ved is vice-chair and member of the Peptides Expert Committee (BIO1) of the United States Pharmacopeia and serves in the governance of the FASEB, American Chemical Society (ACS), and American Peptide Society. Ved earned a Ph.D. in organic chemistry from the University of Lucknow, India.